Kriya Therapeutics Names Sachiyo Minegishi As Chief Financial Officer To Lead Financial Strategy And Support Gene Therapy Programs

Kriya Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative gene therapies for conditions affecting millions globally, has announced the appointment of Sachiyo Minegishi as Chief Financial Officer. In her new role, Ms. Minegishi will lead the execution of Kriya’s corporate strategy, oversee the scaling of financial operations, and support planning for commercialization as the company advances multiple gene therapy programs through clinical development.

Shankar Ramaswamy, M.D., Co-Founder and CEO of Kriya, said that Ms. Minegishi brings extensive financial leadership along with deep experience in corporate development and commercialization within science-driven organizations. He noted that her expertise in scaling biotech companies while maintaining a strong financial foundation will be instrumental as Kriya enters its next phase of growth.

Sachiyo Minegishi expressed her enthusiasm for joining Kriya, highlighting the company’s mission to make gene therapies accessible to patients worldwide. She emphasized the potential impact of Kriya’s programs on patients and their families and said she looks forward to contributing to the company’s advancement through the clinic and its broader strategic objectives.

Ms. Minegishi brings more than 20 years of experience in the biopharmaceutical industry, with a proven record in executive leadership, financial strategy, capital markets, corporate development, and commercial planning. She most recently served as Chief Operating Officer at Rectify Pharma, where she led corporate strategy, finance, and operational execution. Prior to that, she was Chief Financial Officer at Akouos, which was later acquired by Eli Lilly, and she played a key role in the cross-functional global development of gene therapy programs for Sickle Cell Disease at bluebird bio. 

Earlier in her career, she held leadership positions at Aegerion, Human Genome Sciences, Genzyme, and Amgen, and began her professional journey in investment banking at Merrill Lynch. She holds a B.S. in Chemical Engineering and Economics from the Massachusetts Institute of Technology and an M.B.A. from the Wharton School of the University of Pennsylvania. Ms. Minegishi’s appointment strengthens Kriya’s leadership team as the company continues to advance its pipeline of gene therapies and positions itself for growth in the emerging field of transformative genetic medicine.